Analytical Chemists Solving Tough Problems!
Product Testing & Development Specialists

Call us at: 1-800-930-5450 |scientist@avomeen.com

Monthly Archives: December 2013

1912, 2013

2014 Investment Changes for Research and Development

December 19th, 2013|Blog|

Across government, health, industry and all other investors in U.S. research & development, funding has held steady in 2013, with little to no growth in most sectors. However, trends are rising indicating that while total dollars may be stagnant, the purpose and resources of those investments may be of great importance. Studies conducted by Battelle and R&D Magazine as well as IBISWorld project growth in industry specific funding for 2014 and the four years after.

The origination of this money, private corporate funding, implies a greater emphasis on innovation for profit than the R&D industry has seen in the past. These implications are further solidified by the results of a survey which ordered substantiation of success by how individual corporations rank the outcome’s influence on if they invest in the innovation.

Both domestic and multinational corporations ranked publications and patents in their top confirmations of successful R&D, but their other top two results varied. Multinational corporations reported new products to be their number one goal and proof of valuable R&D with patents coming in second followed by profitability and publications. Domestic corporations, however, place publications as their primary result with patents, product quality and productivity coming in at second, third and fourth.

This apparent push for new products, and patentable findings, confirms that the priority of why to spend versus simply the availability of funds truly determines the R&D industry trends. For example, research and development for the chemical industry is expected to grow over the next few years, whose priorities often are focused on developing new formulations for use in consumer products, pharmaceuticals and other industries.

Read the full report synopsis and Avomeen’s comments here.

1112, 2013

Will The Proposed FDA Change for Generic Drugs Prove a Litigation Risk?

December 11th, 2013|Blog|

The U.S. Food and Drug Administration proposed a new rule on November 8th, 2013 which would warrant generic drug companies the same authority over safety information as brand-name manufacturers. This proposal stems from the FDA’s desire to streamline the process for generic companies who discover safety risks and to improve the timeliness of safety label updates.

As of now generic companies are only responsible to duplicate brand-name labels and cannot make any independent changes. Currently, if a generic drug manufacturer does have a safety label concern it must be:

    1. Submitted to the FDA
    2. Reviewed and labeling changes assessed by the brand-name manufacture
    3. Approved by the FDA before the generic drug can make the revision

This rule of reproduction by the Supreme Court has thus far protected generic companies from lawsuits regarding safety labeling as they are only accountable for duplicating what the brand-name drug label states. The impending change would thereby open generic companies to safety-labeling lawsuits, something seemingly absent since a 2011 Supreme Court decision resulting in part from, Pliva v. Mensing.

Public Citizen, a non-profit consumer interest group recently published a report regarding safety hazards and the implications on generic drug safety labeling. In this report they substantiated that length of time on market does not equate to complete safety information. In fact, many serious and even life-threatening risks have been added to drug labels after the product has entered the generic market. These findings invalidating the stance that all side-effects and necessary warnings are addressed during the brand-name only phase, though this period can be twelve to twenty years in some cases.

Proponents of this change also point to the fact that generic drugs make up more than 80% of the U.S. prescription market and therefore the companies must be enabled to take part in updating safety information. They also promote the concern that brand-name manufactures may become unreliable sources of current hazards once generics monopolize the market.

These concerns and others are what prompted the rule which many are saying has been a long time coming. The new rule seeks to ensure consumer safety by allowing generic drug companies authority to immediately change labeling and actively participate with the FDA instead of waiting on the brand-name company. Though the changes are proposed as a means to better the quality of safety updates; the question lingers if the FDA indeed has the authority to grant generic drug manufactures the right to independent label changes when the Supreme Court has consistently held generic drug manufactures to the requirement of duplicating brand labels without the allowance to instate changes without FDA approval. There have also been questions regarding how to ensure consistency in labeling and avoid prescription confusion due to both brand name and generic drugs making possible changes at the same time. In order to address this concern the FDA plans to construct a website which would record all label changes.

The new rule will be open to public comment for a total of 60 days. Should the proposal be instated, generic drug companies will be able to immediately enact drug label changes. It is probable that generic drug companies will be at a greater risk for lawsuits regarding incomplete hazard labeling and will be in need of litigation support services. New generic pharmaceuticals will also need to perform greater testing and research in order to ensure correct safety labeling.

312, 2013

SEM of a Snowflake

December 3rd, 2013|Blog|





The Scanning Electron Microscope (SEM) produces images via electron imaging. The sample’s topography is determined by analyzing signals produced from electron displacement.

In order for conventional SEM imaging to work properly the specimen must be able to conduct an electric charge. For non-metallic samples this requirement is often reached by applying a thin coating of gold, platinum or other metallic substances to the sample in order to produce a clearer image. The snowflake on the right was analyzed after being sputter-coated with platinum at cryogenic temperatures.

Standard microscopes can magnify snowflakes around 30-500x, with the SEM one can view details at over 100,000x. A low temperature SEM was used to generate these images which maintained the integrity of the crystal while magnifying from 93x to 36,000x.

SEM is used to perform surface analysis to solve problems such as:

Coatings Analysis

Deformulation

When SEM is combined with Energy Dispersive Spectroscopy (EDS), SEM-EDS can determine the elemental composition of the sample.

For more information regarding Avomeen’s SEM capabilities and our testing services, or to receive a project quote, call (800) 930-5450 to speak directly with one of our Ph.D. scientists.